Screener / SEC EDGAR /CIK 0001818331 /10-K filed Feb 23, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Health Services

GeneDx Holdings Corp. WGS

Compare with peers Embed
Planned sales, announced before they happen

0 trading plans running, 8 Form 144 notices for $21.7M

10-Q, 10-K and Form 144

What WGS's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Aug 16, 2024 to Nov 16, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
Bryan Dechairo
Chief Operating Officer
Adopted 10b5-1 plan Sep 15, 2025 10-Q Oct 28, 2025
What the company wrote
On September 15, 2025, Bryan Dechairo, our Chief Operating Officer, entered into a written plan for the potential sale of up to an aggregate of 9,374 shares of our Class A common stock, including shares underlying Mr. Dechairo’s RSU awards (the “Dechairo 10b5-1 Plan” and, together with the Stueland 10b5-1 Plan, the “10b5-1 Plans”). The Dechairo 10b5-1 Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and will be effective from February 4, 2026 to September 30, 2026.
Katherine Stueland
Chief Executive Officer
Adopted 10b5-1 plan Sep 11, 2025 10-Q Oct 28, 2025
What the company wrote
On September 11, 2025, Katherine Stueland, our Chief Executive Officer, entered into a written plan for the potential sale of up to an aggregate of 40,000 shares of our Class A common stock, including shares underlying Ms. Stueland’s restricted stock unit (“RSU”) awards (the “Stueland 10b5-1 Plan”). The Stueland 10b5-1 Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and will be effective from April 10, 2026 to October 30, 2026.
Jason Ryan
chairman and a director
Ended 10b5-1 plan Aug 27, 2025 10-Q Oct 28, 2025
What the company wrote
On August 27, 2025, a grantor annuity trust (the “GRAT”) of which Jason Ryan, our chairman and a director, is the trustee, terminated a written plan for the potential transfer of up to an aggregate of 141,356 shares of our Class A common stock that had previously been entered into on November 7, 2024 (the “Ryan GRAT 10b5-1 Plan”). The Ryan GRAT 10b5-1 Plan was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and had provided that it would be effective until March 5, 2027.
Jason Ryan
chairman and a director
Adopted 10b5-1 plan Nov 7, 2024 10-K Feb 20, 2025
What the company wrote
On November 7, 2024, a grantor annuity trust (the “GRAT”) of which Jason Ryan, our chairman and a director, is the trustee, entered into a written plan for the potential transfer of up to an aggregate of 141,356 shares of our Class A common stock (the “Ryan GRAT 10b5-1 Plan”). The Ryan GRAT 10b5-1 Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and will be effective from November 19, 2025 to March 5, 2027.
Kevin Feeley
Chief Financial Officer
Adopted 10b5-1 plan Aug 21, 2024 10-Q Oct 29, 2024
What the company wrote
On August 21, 2024, Kevin Feeley, our Chief Financial Officer, entered into a written plan for the potential sale of up to an aggregate of 117,713 shares of our Class A common stock, including shares underlying Mr. Feeley’s RSU and stock option awards (the “Feeley 10b5-1 Plan”). The Feeley 10b5-1 Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and will be effective from November 21, 2024 to October 30, 2025.
Katherine Stueland
Chief Executive Officer
Adopted 10b5-1 plan Aug 16, 2024 10-Q Oct 29, 2024
What the company wrote
On August 16, 2024, Katherine Stueland, our Chief Executive Officer, entered into a written plan for the potential sale of up to an aggregate of 312,808 shares of our Class A common stock, including shares underlying Ms. Stueland’s restricted stock unit (“RSU”) awards (the “Stueland 10b5-1 Plan”). The Stueland 10b5-1 Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and will be effective from November 15, 2024 to October 30, 2025.

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Sep 1, 2026 Kevin Feeley
Officer
5,410 $458K
Sep 1, 2026 Katherine Stueland
Officer, Director
14,243 $1.2M
Apr 29, 2026 Kevin Feeley
Officer
5,804 $366K
Apr 29, 2026 Katherine Stueland
Director, Officer
16,415 $1.0M
Feb 2, 2026 Bryan Dechairo
Officer
9,374 $930K
Jan 29, 2026 Kevin Feeley
Officer
24,155 $2.4M
Jan 29, 2026 Katherine Stueland
Officer, Director
94,495 $9.3M
Nov 24, 2025 RUCH JOSHUA
Director
38,000 $6.1M

From the Form 144 XML filed with the SEC, since Nov 24, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/WGS/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.